Robert Belknap, MD

Professor, Medicine-Infectious Disease

FacultyPhoto

Download CV

Medical School
  • MD, Ohio State University College of Medicine (1998)
Undergraduate School
  • BS, Kent State University (OH) (1994)
Internship
  • University of Colorado (1998)
Residency
  • University of Colorado, Internal Medicine (2001)
Fellowships
  • University of Colorado, Infectious Disease (2005)
Department
Medicine-Infectious Disease

Professional Titles

  • Executive Director, Public Health Institute at Denver Health

Publications

  • Belknap RW. Current Medical Management of Pulmonary Tuberculosis. Thorac Surg Clin. 2019 Feb;29(1):27-35. PubMed PMID: 30454919
  • Haas MK, Belknap RW. Updates in the Treatment of Active and Latent Tuberculosis. Semin Respir Crit Care Med. 2018 Jun;39(3):297-309. PubMed PMID: 30071545
  • Chee CBE, Reves R, Zhang Y, Belknap R. Latent tuberculosis infection: Opportunities and challenges. Respirology. 2018 Oct;23(10):893-900. PubMed PMID: 29901251
  • Gaensbauer J, Gonzales B, Belknap R, Wilson ML, O'Connor ME. Interferon-Gamma Release Assay-Based Screening for Pediatric Latent Tuberculosis Infection in an Urban Primary Care Network. J Pediatr. 2018 Sep;200:202-209. PubMed PMID: 29866596
  • Beavers SF, Pascopella L, Davidow AL, Mangan JM, Hirsch-Moverman YR, Golub JE, Blumberg HM, Webb RM, Royce RA, Buskin SE, Leonard MK, Weinfurter PC, Belknap RW, Hughes SE, Warkentin JV, Welbel SF, Miller TL, Kundipati SR, Lauzardo M, Barry PM, Katz DJ, Garrett DO, Graviss EA, Flood JM. Tuberculosis Mortality in the United States: Epidemiology and Prevention Opportunities. Ann Am Thorac Soc. 2018 Feb 28. [Epub ahead of print] PubMed PMID: 29490150
  • Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, Leung CC, Schluger NW, Belknap RW, Chaisson RE, Narita M, Machado ES, Lopez M, Sanchez J, Villarino ME, Sterling TR. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials. Ann Am Thorac Soc. 2018 May;15(5):570-580. PubMed PMID: 29393655
  • Gaensbauer J, Aiona K, Haas M, Reves R, Young J, Belknap R. Better Completion of Pediatric Latent Tuberculosis Treatment Using 4 Months of Rifampin in a US-based Tuberculosis Clinic. Pediatr Infect Dis J. 2018 Mar;37(3):224-228. PubMed PMID: 28777204
  • Flynn AG, Aiona K, Haas MK, Reves R, Belknap R. Clinical Characteristics of Active Tuberculosis Diagnosed after Starting Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2019 Nov 27. [Epub ahead of print] PubMed PMID: 31773132
  • Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates with Self-administered Once-weekly Isoniazid-Rifapentine versus Daily Rifampin in Adults with Latent Tuberculosis. Clin Infect Dis. 2020 Sep 11. [Epub ahead of print] PubMed PMID: 32915203
  • Gaensbauer J, Young J, Harasaki C, Aiona K, Belknap R, Haas MK. Interferon-Gamma Release Assay Testing in Children Younger Than 2 Years in a US-Based Health System. Pediatr Infect Dis J. 2020 Sep;39(9):803-807. PubMed PMID: 32804462
  • Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda. Implement Sci. 2020 Aug 12;15(1):65. PubMed PMID: 32787925
  • Haas MK, Belknap RW. Diagnostic Tests for Latent Tuberculosis Infection. Clin Chest Med. 2019 Dec;40(4):829-837. PubMed PMID: 31731987
  • Pettit AC, Stout JE, Belknap R, Benson CA, Séraphin MN, Lauzardo M, Horne DJ, Garfein RS, Maruri F, Ho CS. Optimal testing choice and diagnostic strategies for latent tuberculosis infection among U.S.-born people living with HIV. Clin Infect Dis. 2020 Aug 6. [Epub ahead of print] PubMed PMID: 32761083
  • Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Reply to Swindells et al. : Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. Am J Respir Crit Care Med. 2020 Jul 15;202(2):305-306. PubMed PMID: 32282235
  • Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. Am J Respir Crit Care Med. 2019 Nov 11. [Epub ahead of print] PubMed PMID: 31711306
  • Venkatappa TK, Punnoose R, Katz DJ, Higgins MP, Banaei N, Graviss EA, Belknap RW, Ho CS. Comparing QuantiFERON-TB Gold Plus with Other Tests To Diagnose Mycobacterium tuberculosis Infection. J Clin Microbiol. 2019 Nov;57(11). PubMed PMID: 31462550
  • Sosa LE, Njie GJ, Lobato MN, Morris SB, Buchta W, Casey ML, Goswami ND, Gruden M, Hurst BJ, Khan AR, Kuhar DT, Lewinsohn DM, Mathew TA, Mazurek GH, Reves R, Paulos L, Thanassi W, Will L, Belknap R. Tuberculosis screening, testing, and treatment of U.S. health care personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. Am J Transplant. 2019 Aug;19(8):2383-2387. PubMed PMID: 31343848
  • Sosa LE, Njie GJ, Lobato MN, Bamrah Morris S, Buchta W, Casey ML, Goswami ND, Gruden M, Hurst BJ, Khan AR, Kuhar DT, Lewinsohn DM, Mathew TA, Mazurek GH, Reves R, Paulos L, Thanassi W, Will L, Belknap R. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019 May 17;68(19):439-443. PubMed PMID: 31099768
  • Belknap RW. Current Medical Management of Pulmonary Tuberculosis. Thorac Surg Clin. 2019 Feb;29(1):27-35. PubMed PMID: 30454919
  • Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020 Feb 14;69(1):1-11. PubMed PMID: 32053584
  • Flynn AG, Aiona K, Haas MK, Reves R, Belknap R. Clinical Characteristics of Active Tuberculosis Diagnosed After Starting Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2020 Aug 22;71(5):1320-1323. PubMed PMID: 31773132
  • Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. Am J Respir Crit Care Med. 2020 Mar 1;201(5):598-605. PubMed PMID: 31711306
  • Winglee K, Hill AN, Belknap R, Stout JE, Ayers TL. Variability of interferon-? release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States. Clin Microbiol Infect. 2022 Feb 18. [Epub ahead of print] PubMed PMID: 35183749
  • Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. PLoS Med. 2021 Dec;18(12):e1003875. PubMed PMID: 34914696
  • Radtke KK, Ernest JP, Zhang N, Ammerman NC, Nuermberger E, Belknap R, Boyd R, Sterling TR, Savic RM. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study. Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0170521. PubMed PMID: 34606336
  • Feng PJ, Wu Y, Ho CS, Chinna L, Whelen AC, Largen A, Brostrom R, Reves R, Belknap R, Cattamanchi A, Banaei N. Impact of T-Cell Xtend on T-SPOT. TB Assay in High-Risk Individuals after Delayed Blood Sample Processing. J Clin Microbiol. 2021 Apr 20;59(5). PubMed PMID: 33658266
  • Haas MK, Aiona K, Erlandson KM, Belknap RW. Higher Completion Rates With Self-administered Once-weekly Isoniazid-rifapentine Versus Daily Rifampin in Adults With Latent Tuberculosis. Clin Infect Dis. 2021 Nov 2;73(9):e3459-e3467. PubMed PMID: 32915203
  • Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, Millet JP, Cayla JA, Scott NA, Borisov A, Gandhi NR. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2023 Feb 23. [Epub ahead of print] PubMed PMID: 36815322
  • Winglee K, Hill AN, Belknap R, Stout JE, Ayers TL. Variability of interferon-? release assays in people at high risk of tuberculosis infection or progression to tuberculosis disease living in the United States. Clin Microbiol Infect. 2022 Jul;28(7):1023.e1-1023.e7. PubMed PMID: 35183749
  • Pettit AC, Stout JE, Belknap R, Benson CA, Séraphin MN, Lauzardo M, Horne DJ, Garfein RS, Maruri F, Ho CS. Optimal Testing Choice and Diagnostic Strategies for Latent Tuberculosis Infection Among US-Born People Living with Human Immunodeficiency Virus (HIV). Clin Infect Dis. 2021 Oct 5;73(7):e2278-e2284. PubMed PMID: 32761083
  • Li R, Deutsch-Feldman M, Adams T, Law M, Biak C, Pitcher E, Drees M, Hernandez-Romieu AC, Filardo TD, Cropper T, Martinez A, Wyatt Wilson W, Althomsons SP, Morris SB, Wortham JM, Benowitz I, Schwartz NG, White K, Haddad MB, Glowicz JB. Transmission of Mycobacterium tuberculosis to Healthcare Personnel Resulting From Contaminated Bone Graft Material, United States, June 2021-August 2022. Clin Infect Dis. 2023 May 24;76(10):1847-1849. PubMed PMID: 36660866
  • Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, Millet JP, Caylà JA, Scott NA, Borisov A, Gandhi NR. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2023 Jun 16;76(12):2090-2097. PubMed PMID: 36815322
  • Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 Sep;11(9):782-790. PubMed PMID: 36966788
  • Zavala S, Winglee K, Ho CS, Pettit AC, Ahmed A, Katz DJ, Belknap RW, Stout JE. Examining Test Cutoffs to Optimize Diagnosis of Latent Tuberculosis Infection in People Born Outside the United States. Ann Am Thorac Soc. 2023 Sep;20(9):1258-1266. PubMed PMID: 37159954
  • Scott NA, Sadowski C, Vernon A, Arevalo B, Beer K, Borisov A, Cayla JA, Chen M, Feng PJ, Moro RN, Holland DP, Martinson N, Millet JP, Miro JM, Belknap R. Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine. Contemp Clin Trials. 2023 Jun;129:107173. PubMed PMID: 37004811
  • Vonnahme LA, Raykin J, Jones M, Oakley J, Puro J, Langer A, Aiona K, Belknap R, Ayers T, Todd J, Winglee K. Using Electronic Health Record Data to Measure the Latent Tuberculosis Infection Care Cascade in Safety-Net Primary Care Clinics. AJPM Focus. 2023 Dec;2(4):100148. PubMed PMID: 37941821

Practice Locations

Denver Health
777 Bannock St
Denver, CO 80204
303-436-6000

Hospital Affiliation
  • Denver Health Medical Center

Specialty Information

Specialties
  • Infectious Disease, Board Certification

School of Medicine

CU Anschutz
Fitzsimons Building

13001 East 17th Place

Aurora, CO 80045

303.724.5375

School
General
Students